Hayden F G, Monto A S
Antimicrob Agents Chemother. 1986 Feb;29(2):339-41. doi: 10.1128/AAC.29.2.339.
In a randomized, double-blind trial involving patients with uncomplicated influenza A H3N2 subtype virus infection, rimantadine treatment (200 mg/day for 5 days) was associated with significant reductions in nasal secretion viral titers (days 2 through 4), maximal temperature (days 2 and 3), time until defervescence (mean, 37 h shorter), and systemic symptoms compared with placebo treatment.
在一项针对无并发症的甲型H3N2亚型流感病毒感染患者的随机双盲试验中,与安慰剂治疗相比,金刚乙胺治疗(200毫克/天,持续5天)可使鼻分泌物病毒滴度(第2至4天)、最高体温(第2和3天)、退热时间(平均缩短37小时)以及全身症状显著降低。